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The health system in Australia is showing stress from an
ageing population, increase in chronic diseases and a
reduced ability for the public to easily access doctors.
To add to the stress, it is predicted that the shortage in
general practitioners in Australia will continue.1 These
pressures highlight the need for the development of new
primary care models.
Australian pharmacists wish to further utilise their
extensive drug and therapeutics knowledge to enhance
patient care. The continuing ‘down-scheduling’ of
prescription-only medicines in Australia is making an
increasing range of medicines available for community
pharmacists to prescribe over–the–counter. A logical
expansion of this phenomenon and other patient-focused
services provided by pharmacists is to extend prescribing
by pharmacists to a broader range of medicines.
Pharmacists in the UK have achieved this objective with
the introduction of supplementary (dependent)
prescribing in 2003 followed by independent prescribing
in 2006. The basis for the establishment of pharmacist
prescribing in the UK was to improve patients’ access to
medicines and better utilise the expertise of health
professionals. Supplementary prescribers implement a
clinical management plan for patients in agreement with
a prescriber, while independent prescribers make an initial
assessment of patients and make decisions about their
clinical management including prescribing.
In Australia there has been a move towards allied
health professionals prescribing within their professional
competence. For example, nurse practitioners have started
prescribing, and podiatrists and optometrists have been
granted limited prescribing rights. Remote area nurses
have had a long history of supplementary prescribing
and are progressing to independent prescribing. There
have been preliminary studies on the attitudes of
Australian pharmacists to expanded prescribing and
possible models that could improve patient access to
medicines.2-4
We recently completed a national survey of
Australian pharmacists’ views on expanding their
prescribing role.5 Respondents represented all areas of
pharmacy practice and gave their views in the absence
of extended pharmacist prescribing.5 Respondents
strongly favoured supplementary prescribing and noted
that an expanded prescribing role would better use their
skills and ease the workload on general practitioners.5
Around 30% of respondents supported the introduction
of supplementary and independent prescribing and a
minority supported an independent prescribing model.5
Most respondents identified that to assume
expanded prescribing roles, additional skills in disease
diagnosis and patient assessment would be required.5
In the UK, prior to undertaking the mandatory education
and training for prescribing roles, pharmacists are
required to have at least two years of post-registration
patient-related experience. The training consists of 26
days of university-based study followed by at least 12
days of supervised practical experience with a designated
medical practitioner. Weeks et al.6 in this issue describe
their experiences with such a course and is useful
background as courses will need to be developed to
provide the necessary competencies for Australian
pharmacists to move into expanded prescribing roles.
The strong grassroots support from the profession for
such a move, identified in our survey, gives the
professional bodies a sound basis to lobby government
and position the profession accordingly.5
The strong support for supplementary prescribing
could indicate that pharmacists would like to progress
to an expanded prescribing role in a stepwise manner.
This is a sound approach as it will allow the development
of necessary competencies in a suitable environment.
Inevitably tension between supplementary and
independent prescribing roles could become an issue. It
is hoped the latter model would be the ultimate objective
of an expansion of our professional roles.
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The Institute of Medicine has identified medication
safety as one of the key issues that must be addressed to
reduce medication errors.1 Given that pharmacists are
medication experts, it is not only a professional but a
moral and ethical duty for pharmacists to take ownership
and leadership for medication safety.
Medication safety
Safety is the foundation on which quality is built.
Medication safety, therefore, must be an integral
component of the entire medication management and use
process, i.e. from procurement, distribution, to use and
monitoring. At every step, pharmacists must pay attention
to the risks identified, undertake a risk assessment and
implement risk mitigation, if needed. Only then can we
reduce preventable adverse drug events, medication
errors and patient harm.
Rinehart2 has surmised that conundrums will
continue to occur as health care evolves and that
pharmacists must take leadership in the management and
resolution of medication safety conundrums to maintain
a culture of safety and avoid patient harm.
The majority of medication safety conundrums
encountered by pharmacists are due but not limited to
misunderstanding, miscommunication or non-
communication, and system and process failures. A safety
culture that is open, transparent, supportive and
committed to learning will lead to effective error and risk
management at individual and organisational levels and
should be encouraged.
Exploring error incidence in the medication use
process (i.e. prescribing, transcription, dispensing and
drug administration) on the wards, Leape et al.3 and Bates4
reported that prescribing (Leape 39%, Bates 49%) and
drug administration (Leape 38%, Bates 26%) accounted
for the majority of errors with transcription (Leape 12%,
Bates 11%) and dispensing (Leape 11%, Bates 14%)
coming in last. Computerised Prescriber Order Entry and
pharmacist interventions during prescribing and drug
administration are crucial and has the most impact in
reducing errors. As for transcription and dispensing, use
of information technology, automation and process re-
engineering are recommended. These are examples of how
pharmacists can focus on key medication safety issues
and tackle them systematically and effectively.
Advantages
Pharmacists involvement and leadership in medication
safety gives them the opportunity to fix what is wrong.
For example, pharmacists can improve facilities, staffing
levels, streamline processes, increase collaboration with
doctors and nurses, and reduce waste. This would allow
continuous improvement to take root, which would
benefit staff, the department, organisation and ultimately
the patient. The establishment of an institutional
medication safety committee that is championed by a
medication safety officer who is a pharmacist is a viable
way of doing so. The medication safety committee can
advocate collection of medication error data, perform
analysis using established tools like root-cause analysis
and make relevant recommendations to improve safety.
Disadvantages
On the flip side, the medication safety agenda can mean
more accountability, more bureaucracy, more work, and
can expose the profession’s weaknesses. Medication
safety can often be expensive because of improvements
to facilities, equipment and implementation of technology.
Medication safety can also increase resistance from the
‘nay sayers’ and those who do not want to change.
Cost
The cost of adverse drug events, medication errors and
patient harm has been enumerated in numerous reports/
studies and runs into billions of dollars annually.1,5 This
is notwithstanding the mental, emotional and personal
suffering that affects patients and their families and
pharmacists and their families. This enormous social cost
to the community is relevant and important.
 Can Pharmacists Afford not to Champion
Medication Safety?
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